Investors & Media

Investors & Media

Welcome to our investor page

Harnessing the immune system’s full potential to fight human disease.

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we and our collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside a diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.


Press Releases

11 January 2022

BioNTech and InstaDeep Developed and Successfully Tested Early Warning System t..

10 January 2022

BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi..

5 January 2022

Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mR..

Press releases (more)

Upcoming Events

March 30, 2022

Full Year and Fourth Quarter 2021 Earnings Call

May 9, 2022

First Quarter 2022 Earnings Call

August 8, 2022

Second Quarter 2022 Earnings Call

Upcoming events (more)

Stock Quote

Jan 17, 2022 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.